UGT2B17 and B-cell chronic lymphocytic leukemia: In conclusion, our findings imply a relevant anti-oncogenic function of PGE2 in CLL cells that is blocked by high UGT2B17 expression, through a direct metabolic inactivation of PGE2 and altered PGE2-related gene expression leading to PGE2 unresponsiveness.